Pharmadrug Inc. PHRX
CNSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -70.04% | -68.69% | |||
| Depreciation & Amortization | -1.09% | 2.22% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -50.31% | -60.98% | |||
| Operating Income | 50.31% | 60.98% | |||
| Income Before Tax | -25.87% | -39.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -25.87% | -39.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -39.73% | 1.39% | |||
| Net Income | -29.39% | -42.22% | |||
| EBIT | 50.31% | 60.98% | |||
| EBITDA | 70.04% | 68.69% | |||
| EPS Basic | -30.00% | -11.11% | |||
| Normalized Basic EPS | -33.33% | 40.00% | |||
| EPS Diluted | -30.00% | -11.11% | |||
| Normalized Diluted EPS | -33.33% | 40.00% | |||
| Average Basic Shares Outstanding | 0.00% | 24.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 24.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||